Drug · DIN 02497603
RYBELSUS
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since April 19, 2020; first marketed April 19, 2020.
- Drug Identification Number (DIN)
- 02497603
- Company (DIN owner)
- Novo Nordisk Canada IncMississauga, Ontario, Canada
- Schedule
- Prescription; Schedule d
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Semaglutide A10BJ06
- Class
- Human
- Record last updated
- August 13, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| SEMAGLUTIDE | 7 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- March 30, 2020: NOC 23396New Drug Submission (NDS)
Other DINs named RYBELSUS
- DIN 02497581 · Marketed
- DIN 02497611 · Marketed
- DIN 02551012 · Marketed
- DIN 02551020 · Marketed
- DIN 02551039 · Marketed